A new sub-study suggests that using a sirolimus-eluting balloon (SEB), a drug-coated balloon, can reduce the number of stents ...
Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of ...
A new sub-study suggests that using a sirolimus-eluting balloon (SEB), a drug-coated balloon, can reduce the number of stents ...
Dallas, TX - In a study hailed as the "first rigorous analysis of the costs of brachytherapy," Dr David J Cohen (Beth Israel Deaconess Medical Center, Boston, MA) and colleagues report that the cost ...
The noninferiority PERSEUS workhorse trial randomized – in a 3:1 ratio – 1262 patients with lesions of less than 28 mm to treatment with the Taxus Element (n = 942) or the Taxus Express® PES (n = 320) ...
Please provide your email address to receive an email when new articles are posted on . A sirolimus-eluting balloon was noninferior to drug-eluting stents in treating de novo coronary lesions. The ...
(BETHESDA, MD)--The use of medicated stents markedly improves the clinical outcomes of patients who develop blockages in aging veins surgically grafted onto the heart, according to a just-published ...
The global drug-eluting stents market size, valued at USD 9.2 Billion in 2025, is projected to reach USD 14.5 Billion by 2034 ...
Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A bioadaptor implant was linked to fewer CV event rates ...
United States As the healthcare industry reforms to convert the current fee-for-service model to fee-for-value model, intense focus has been placed on the reduction in patient complications, and ...
Drug-eluting stents are safe to use in older patients undergoing percutaneous coronary interventions regardless of renal function, researchers concluded. In addition, use of these stents are ...